Plus Therapeutics Has Acquired Assets For The Synergistic Leptomeningeal Metastases Diagnostic Platform, Financial Terms Not Disclosed; Topline Clinical Trial Data On The Foresee Trial, Met Its Primary Endpoint Of Clinical Utility

5/9/24 11:36:06 AM ET

Medical/Dental Instruments

Health Care

Get the next $PSTV alert in real time by email

Company acquired assets for the synergistic leptomeningeal metastases (LM) diagnostic platform, "CNSide™" and discussed potential partnering opportunities

CNSide can significantly improve LM diagnostic accuracy and the market size for Plus' lead LM radiotherapeutic candidate rhenium (Re186) obisbemeda

Company summarized topline data from the FORESEE clinical trial planned for complete presentation at the SNO/ASCO Meeting in August 2024

Call replay & transcript available via the link below

Get the next $PSTV alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PSTV

Date	Price Target	Rating	Analyst

More analyst ratings

Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance payment for leptomeningeal cancer targeted radiotherapeutic development program AUSTIN, Texas, June 07, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced the appointment of Dr. Greg Fuller a
6/7/24 7:30:00 AM ET
$PSTV
Medical/Dental Instruments
Health Care
Plus Therapeutics Strengthens Clinical Program with the Appointment of Pius Maliakal as Vice President of Clinical Operations
AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced the appointment of Pius Maliakal, M. Pharm., Ph.D., as Vice President of Clinical Operations. Dr. Maliakal will be responsible for the strategy and planning of key clinical operational initiatives, focusing on advancing the Company's lead clinical trials, ReSPECT-GBM and ReSPECT-LM, and further developing the broader pipeline. Dr. Maliakal is an accomplished R&D professional who brings over 20 years of global and domestic
7/27/23 4:05:00 PM ET
$PSTV
Medical/Dental Instruments
Health Care
Plus Therapeutics Announces the Appointment of Industry Veteran, Norman LaFrance, M.D., as the Company's Chief Medical Officer
AUSTIN, Texas, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced the appointment of Norman LaFrance, M.D. to the position of Chief Medical Officer and Senior Vice President. "We are delighted to have Dr. LaFrance onboard as he brings several decades of highly relevant clinical, regulatory and commercial expertise to the Plus Therapeutics management team," stated Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics. "His proven track record in radiotherapeutics and drug developme
9/13/21 7:00:00 AM ET
$PSTV
Medical/Dental Instruments
Health Care

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
AUSTIN, Texas and INDIANAPOLIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, and SpectronRx, a leading radiopharmaceutical contract developer and manufacturer, announced the signing of a Manufacturing Services Agreement (MSA) for the production of Rhenium (186Re) Obisbemeda, an innovative radiotherapy for CNS cancers, including leptomeningeal metastases and recurrent glioblastoma. "In 2025, we intend to begin late-stage clinical trials and are actively preparing for commercial level product demand, therefore now is the time to expand our suppl
11/6/24 7:30:00 AM ET
$PSTV
Medical/Dental Instruments
Health Care
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
AUSTIN, Texas, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report third quarter 2024 financial results on Thursday, November 14, 2024, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Webcast and Conference Call Date/Time:Thursday, November 14, 2024 @ 5:00 PM ETWebcast:https://edge.media-server.com/mmc/p/rdthwekoDial-in Link:http
11/5/24 7:30:00 AM ET
$PSTV
Medical/Dental Instruments
Health Care
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
Company will present results from the ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda for leptomeningeal metastases (LM) and discuss its plan for continued clinical development Company will present results from the FORESEE Trial of circulating tumors cells for improved diagnosis and disease monitoring of LM Company to host an educational symposium featuring clinical experts discussing LM and Plus' recent announcements for its LM therapeutic and diagnostic programs AUSTIN, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with
10/29/24 7:30:00 AM ET
$PSTV
Medical/Dental Instruments
Health Care

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
AUSTIN, Texas, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report third quarter 2024 financial results on Thursday, November 14, 2024, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Webcast and Conference Call Date/Time:Thursday, November 14, 2024 @ 5:00 PM ETWebcast:https://edge.media-server.com/mmc/p/rdthwekoDial-in Link:http
11/5/24 7:30:00 AM ET
$PSTV
Medical/Dental Instruments
Health Care
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Presented Positive Interim ReSPECT-LM Phase 1 Data for Rhenium (186Re) Obisbemeda for Leptomeningeal MetastasesPresented Positive Topline Clinical Trial Results for CNSide diagnostic in the FORESEE trialManagement to host conference call August 14, 2024 at 5:00 p.m. ET AUSTIN, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced financial results for the second quarter ended June 30, 2024, and provided an overview of recent and upcoming business highlights. Q2 2024 RECENT HIG
8/14/24 4:16:00 PM ET
$PSTV
Medical/Dental Instruments
Health Care
Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024
AUSTIN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report second quarter 2024 financial results on Wednesday, August 14, 2024, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Webcast and Conference CallDate/Time:Wednesday, August 14, 2024 @ 5:00 PM ETWebcast:https://edge.media-server.com/mmc/p/mtnrwhh5Dial-in Link:https:/
8/8/24 7:30:00 AM ET
$PSTV
Medical/Dental Instruments
Health Care

Plus Therapeutics Has Acquired Assets For The Synergistic Leptomeningeal Metastases Diagnostic Platform, Financial Terms Not Disclosed; Topline Clinical Trial Data On The Foresee Trial, Met Its Primary Endpoint Of Clinical Utility

Chat with this insight

Recent Analyst Ratings for $PSTV

$PSTV Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Hawkins Richard J bought $5,996 worth of shares (4,000 units at $1.50), increasing direct ownership by 36% to 15,188 units (SEC Form 4)

Director Hawkins Richard J bought $8,512 worth of shares (6,285 units at $1.35), increasing direct ownership by 128% to 11,188 units (SEC Form 4)

Director Petersen Greg bought $16,875 worth of shares (12,500 units at $1.35), increasing direct ownership by 34% to 48,921 units (SEC Form 4)

$PSTV Leadership Updates

Live Leadership Updates

$PSTV Press Releases

Fastest customizable press release news feed in the world

$PSTV Financials

Live finance-specific insights

$PSTV Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$PSTV SEC Filings

Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT

Plus Therapeutics Strengthens Clinical Program with the Appointment of Pius Maliakal as Vice President of Clinical Operations

Plus Therapeutics Announces the Appointment of Industry Veteran, Norman LaFrance, M.D., as the Company's Chief Medical Officer

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024

Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024

Director Hawkins Richard J bought $5,996 worth of shares (4,000 units at $1.50), increasing direct ownership by 36% to 15,188 units (SEC Form 4)

Director Hawkins Richard J bought $8,512 worth of shares (6,285 units at $1.35), increasing direct ownership by 128% to 11,188 units (SEC Form 4)

Director Petersen Greg bought $16,875 worth of shares (12,500 units at $1.35), increasing direct ownership by 34% to 48,921 units (SEC Form 4)

SEC Form 424B3 filed by PLUS THERAPEUTICS Inc.

SEC Form 8-K filed by PLUS THERAPEUTICS Inc.

SEC Form S-3 filed by PLUS THERAPEUTICS Inc.

$PSTV Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright initiated coverage on Plus Therapeutics

HC Wainwright & Co. initiated coverage on Plus Therapeutics with a new price target

Ladenburg Thalmann initiated coverage on Plus Therapeutics with a new price target

$PSTV Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by PLUS THERAPEUTICS Inc.

SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

$PSTV Market Insights

Live Market Insights

PLUS THERAPEUTICS Says Greg Fuller Joins Company As Vice President Of Medical Affairs And Medical Director; Reports $3.3M Advance Payment From CPRIT

Plus Therapeutics Q1 2024 GAAP EPS $(0.75) Beats $(1.09) Estimate, Sales $1.677M Miss $1.688M Estimate

Plus Therapeutics Has Acquired Assets For The Synergistic Leptomeningeal Metastases Diagnostic Platform, Financial Terms Not Disclosed; Topline Clinical Trial Data On The Foresee Trial, Met Its Primary Endpoint Of Clinical Utility

Recent Analyst Ratings for
$PSTV

$PSTV
Insider Purchases

$PSTV
Leadership Updates

$PSTV
Press Releases

$PSTV
Financials

$PSTV
Insider Trading

$PSTV
SEC Filings

$PSTV
Analyst Ratings

$PSTV
Large Ownership Changes

$PSTV
Market Insights